Premium
Activity in vitro of twelve antibiotics against clinical isolates of extended‐spectrum beta‐lactamase producing Escherichia coli
Author(s) -
Sorlózano Antonio,
Gutiérrez José,
Romero José María,
de Dios Luna Juan,
Damas Miguel,
Piédrola Gonzalo
Publication year - 2007
Publication title -
journal of basic microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.58
H-Index - 54
eISSN - 1521-4028
pISSN - 0233-111X
DOI - 10.1002/jobm.200710318
Subject(s) - ertapenem , cefepime , cefoxitin , microbiology and biotechnology , piperacillin , imipenem , ceftazidime , ciprofloxacin , beta lactamase , antibiotics , tobramycin , amikacin , broth microdilution , tazobactam , carbapenem , piperacillin/tazobactam , beta lactamase inhibitors , clavulanic acid , chemistry , amoxicillin , minimum inhibitory concentration , biology , escherichia coli , antibiotic resistance , bacteria , gentamicin , staphylococcus aureus , biochemistry , genetics , gene , pseudomonas aeruginosa
Twelve beta‐lactam and non‐beta‐lactam antibiotics were evaluated against 115 clinical isolates of extended‐spectrum beta‐lactamase‐producing (ESBLs) Escherichia coli using a broth microdilution test in accordance with the CLSI guidelines. Susceptibility was 100% with imipenem, ertapenem and amikacin, 95.7% with piperacillin‐tazobactam, 91.3% with cefoxitin, 87% with tobramycin, 81.7% with amoxicillin‐clavulanate, 80% with cefepime, 67.8% with ceftazidime, 27.8% with ciprofloxacin, 27% with levofloxacin and 13% with ceftriaxone. Ertapenem was the antibiotic with the lowest minimum inhibitory concentrations (MICs) for all isolates. There were no clinically relevant differences in the activity of the antibiotics in the presence of CTX‐M‐9 or SHV enzymes. (© 2007 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim)